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returned the study survey. The SF-36 instrument was used to measure HRQOL and
comparedwith the provincial norm. The secondwavewas a random sample of 323
respondents from the initial 1617 first-wave respondents, who were interviewed
with an identical instrument 3 years after the earthquake. ANOVA and t-tests were
used to compare SF-36 scores among residents by earthquake impact levels;
against a provincial norm; and between 8months and 3 years. RESULTS: The SF-36
subscale scores differed by the impact level of earthquake except for RP. Compared
with the Sichuan provincial norm, all subscale SF-36 scores of the first-wave re-
spondents were lower atmonth 8 (all p-values0.001). Seven subscale scores of RP,
BP, GH, VT, SF, RE, and MH at 3 years were statistically lower than the provincial
norm (all p-values0.05). Among the second-wave respondents, all the 3-year
SF-36 subscale scores improved in comparison to those taken 8 months after the
earthquake except for RP and SF. CONCLUSIONS: The HRQOL declined compared
with the norm, especially the psychological aspects. Furthermore, the HRQOL 3
years after the earthquake were persistently lower than the norm level, despite its
recovery from 8-month level.
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OBJECTIVES: In adults with executive dysfunction and mild major depressive dis-
order (MDD), lisdexamfetamine dimesylate (LDX) augmentation significantly im-
proved executive dysfunction (primary endpoint) on the Behavior Rating Inventory
of Executive Function–Adult Version (BRIEF-A). Because cognitive impairment can
affect functioning, including the ability to work, we describe LDX effects on func-
tional outcomes from the aforementioned study. METHODS: This double-blind,
placebo-controlled study enrolled participants (18–55 y)withmildMDD (Montgom-
ery-Åsberg Depression Rating Scale total score 18) and executive dysfunction
(BRIEF-A Global Executive Composite T-score60) on stable SSRI monotherapy for
8 weeks. After 2 weeks of screening, participants were randomized to 9 weeks of
double-blind LDX (week 1: 20 mg/d; weeks 2–6: maintain or increase LDX in 10-mg
increments weekly to 70 mg/d; weeks 7–9: maintain optimized dose) or placebo
augmentation, followed by 2 weeks of single-blind placebo. Prespecified secondary
functional endpoints included theQuality of Life Enjoyment and SatisfactionQues-
tionnaire (Q-LES-Q) and Endicott Work Productivity Scale (EWPS). Analyses in-
cluded analysis of covariance in randomized participants who took 1 study drug
dose and had 1 postbaseline BRIEF-A assessment. RESULTS: Of 143 randomized
participants (placebo, 72; LDX, 71), 119 completed double-blind treatment (placebo,
59; LDX, 60). For the Q-LES-Q, least squares (LS) mean (95% CI) treatment differ-
ences at endpoint significantly favored LDX in 5 of 10 domains: “physical health
activities” (9.6 [3.6, 15.6]; p0.0020), “feelings” (5.8 [0.0, 11.6]; p0.0481), “work” (9.1
[2.0, 16.1]; p0.0123), “household duties” (8.8 [2.2, 15.4]; p0.0094), and “general
activities” (6.2 [1.0, 11.4]; p0.0191); no differentiation was observed in the other
domains. For the EWPS, the LS mean (95% CI) treatment difference at endpoint
numerically favored LDX but was not statistically significant (–4.4 [–10.9, 2.0;
p0.1731). CONCLUSIONS: These findings suggest LDX augmentation modestly
improves functional outcomes in adults with partially or fully remitted MDD.
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OBJECTIVES: Schizophrenic patients often remain symptomaticwith predominant
(or persistent) negative symptoms (PNS) despite receiving antipsychotic therapy.
Negative symptoms might include social withdrawal, poverty of speech, apathy,
inability to experience pleasure, limited emotional expression, or defects in atten-
tion control. Several definitions of PNS exist. The purpose of this study is to de-
scribe PNS population according to several definitions. METHODS: Definitions of
patients with PNS were searched in literature, and applied to patients from the
EuroSC cohort (N288 in France, N618 in Germany andN302 in UK). Five assess-
ments including Positive and Negative Symptoms Scale (PANSS) were performed
over 2 years. The extent of overlap between definitions was assessed at baseline,
and pathways of patients with PNS were explored over 2 years. Bivariate analyses
were conducted to compare patients with PNS to others in terms of quality of life
(QoL), side effects, functioning and depression. RESULTS: Six definitions were
found, all based on PANSS subscores. Results differed according to countries, with
an average of 41% of patients with PNS in France, 24% in UK and 13% in Germany.
For all definitions, about 60% of patients with PNS at baseline still had PNS after 6
months, and about 40% still had PNS after 2 years. PNS patients were found to have
a lower QoL (EQ-5D: 0.70 vs. 0.74 on average), more severe side-effects (SAS: 4.2
vs.3.2 on average), lower functioning (GAF: 40 vs. 54 on average) and to be more
depressed (CDSS: 3.7 vs.2.6 on average). CONCLUSIONS: Our study suggests that
patients with PNS form a stable population overtime with higher clinical burden.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of patients with PNS. Further analyses on clinical
and economical burden of these patients are required.
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OBJECTIVES: Anxiety disorders represent the most common psychiatric illness in
the US Pharmacotherapy is the most common approach to treat anxiety disorders.
Our objective is to determine the extent to which patients with anxiety disorder
seek pharmacological treatment and to examine factors that are associated with
the pharmacological treatment utilization. METHODS: We evaluated Medical Ex-
penditures Panel Survey (MEPS) data (data pooled for survey calendar years 2005-
2009). Adult MEPS respondents (age17), identified as having anxiety disorder con-
dition (n  3412) were included in the study. Andersen behavioral model of health
services utilization was used as the conceptual framework for the study. Depen-
dent variables were defined as utilization of anti-anxiety medications (model A)
and number of prescriptions for anxiety disorders (model B). Independent vari-
ables, i.e. predisposing, enabling and need variables, were defined for each model
based on current literature and availability in MEPS. Logistic regression (model A)
and Poisson regression (model B) analyses were conducted to find the predictors of
medication utilization as well as the number of prescriptions. RESULTS: Sixty-one
percent of adults with anxiety disorder take anti-anxiety medication (95% CI: 59%,
63%). Formodel A, significant variables were race (Native Hawaiian/Pacific Islander
versus white, OR0.001, p0.001), education (no education versus elementary
school, OR 0.295, p0.039), prescription drug insurance coverage (no coverage
versus coverage for at least one round in year, OR 0.768, p 0.005), insurance
coverage (private insurance versus public insurance, OR 0.749, p 0.034), having
irritable bowel syndrome (IBS) (OR2.951, p0.016), andmood disorder (OR2.194,
p0.0001). For model B, significant variables were cost index (-0.391, p0.0001),
number of comorbidities (0.163, p0.0001) and age (-0.174, p 0.043).
CONCLUSIONS: Utilization rate of anti-anxiety medications among adult patients
with anxiety disorder is high. Demographic variables are less likely to affect this
utilization, while enabling and clinical need variables are highly influential.
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OBJECTIVES: To compare deviation rates from the labeled average daily consump-
tion (DACON) in patients with ADHD initiated on lisdexamfetamine dimesylate
(LDX) versus other once-daily FDA-approved stimulant medications. METHODS:
Patients with ADHD initiated on a stimulant medication on or after February 23,
2007 were selected from a large US claims database. Based on age and previous
treatment, patientswere classified into treatment-naïve or previously-treated chil-
dren/adolescents (6-17 years old), and adults (18 years old), respectively. Further-
more, based on the initiated medication, patients were classified into 4 cohorts:
LDX, methylphenidate HCl (OROS MPH), other methylphenidate/dexmethylpheni-
date HCl long acting (MPH LA), and amphetamine long acting (AMPH LA). DACON
was defined as the quantity of units supplied divided by the number of days of
supply in the 12-month study period. The proportion of patientswhodeviated from
the labeledDACON (ie, DACON1 pill/day) and the likelihood of deviation from the
labeled DACONwere compared across cohorts using chi-square tests andmultiple
logistic regression models, respectively. RESULTS: Across all subgroups, the pro-
portion of patients who deviated from the labeled DACONwas significantly higher
in each treatment cohort (range: 7.4%-29.4%) versus the LDX cohort (range: 2.9%-
9.9%) (all p0.001). After adjustments, uniformly across all subgroups, patients in
each treatment cohort were significantly more likely to deviate from the labeled
DACON versus LDX-treated patients. In children/adolescent groups, odds ratios
ranged from 2.6 to 3.7 and 2.9 to 4.1 in the previously-treated and the treatment-
naïve cohorts, respectively (all p0.001). In adult groups, odds ratios ranged from
2.1 to 4.0 and 2.1 to 4.1 in the previously-treated and the treatment-naïve cohorts,
respectively (all p0.001). CONCLUSIONS: Findings suggest that LDX-treated pa-
tients were more likely to adhere to the dosing regimen recommended in FDA
labels and were less likely to have a DACON 1 compared with patients treated
with other once-daily stimulant ADHD medications.
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OBJECTIVES: Significant increase in antidepressant use has been described over
the last two decades. To date, no study has compared trends in antidepressant use
in countries with different economic characteristics. TheOBJECTIVES were to de-
scribe and compare the growth of antidepressants use by pharmacologic class from
the late 1990s onward among 10 countries and the relation to the evolution of the
Gross Domestic Product (GDP), total health expenditures (HE) and the pharmaceu-
tical expenditures (PE) in each country.METHODS: Retrospective analysis of sales
data extracted from IMSHealth commercial database between 1999 and 2008 in US,
France, Germany, UK, Spain, Italy, Greece, Poland, Hungary and the Czech Repub-
lic. Description of antidepressant volume in Defined Daily Dose (DDD) per capita,
comparison of growth (% change between 1999 and 2008) and descriptive relation-
ship with % change in GPD, PE and HE. RESULTS: Antidepressant use increased
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